Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and ...

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Amplia Therapeutics and Immutep have released clinical trial results that promise more effective treatments for pancreatic and lung cancers ...

The ASX 300 stock highlights that ~92% of all evaluable patients have a programmed death-ligand 1 (PD-L1) Tumor Proportion ...

Investing.com -- Citi downgraded both AbbVie (NYSE: ABBV) and Merck (NSE: PROR) to Neutral in separate notes Wednesday, ...

President Trump has elevated an issue Democrats have been jawboning about for years. On Monday the president issued an ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

On May 12th the president signed an executive order that seeks to force drugmakers to reduce their prices in America to align ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.